Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
